Analysis of ROC showed that CSF levels of FABP3 may significantly discriminate AD patients from controls (AUC = 0.881, p < 0.001), with 84.6% of accuracy, 88.2% specificity and 77.8% sensitivity. Here, FABP3 is linked to Alzheimer disease.